Anticonvulsants Market PPT

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. ANTICONVULSANTS MARKET ANALYSIS • Anticonvulsants Market, by Drug Class (Barbiturates, Benzodiazepines, Hydantoins, Succinimides, and Others), by Application (Epilepsy, Migraine, Fibromyalgia, Neuropathic Pain, Anxiety, and Bipolar Disorder), by Route of Administration (Enteral, Parenteral, and Topical), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

3. Anticonvulsants are pharmaceutical agents used for the treatment of epileptic seizures. These are commonly known as anti-epileptic drugs or anti-seizure drugs. Epilepsy is a chronic central nervous system (neurological) disorder, wherein brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. Anticonvulsant drugs are also used for the treatment of bipolar disorder, borderline personality disorder, fibromyalgia, and neuropathic pain. Epilepsy can affect any individual at any age. According to Epilepsy Society of U.K. 2019 data, over 20 drugs are available for the treatment of epilepsy such as barbiturates, carboxamides, carbamates, and GABA analogs and around 25 generics are present in the market.

4. Global Anticonvulsants Market: Drivers The anticonvulsants market size is expected to increase over the forecast period, owing to rising prevalence of epilepsy globally. According to the World Health Organization (WHO) January 2019 report, around 50 million people are affected by epilepsy worldwide. Moreover, it is estimated that around 2.4 million new cases of epilepsy are diagnosed every year, globally. Increasing approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA) are highly contributing to increase in the anticonvulsants market revenue. There are around 24 anticonvulsants drugs approved by the FDA. In 2018, FDA approved the first drug containing an active ingredient derived from marijuana to treat rare, severe forms of epilepsy such as Lennox-Gastaut syndrome and Dravet syndrome.

5. Global Anticonvulsants Market: Drivers The anticonvulsants market size is expected to increase over the forecast period, owing to rising prevalence of epilepsy globally. According to the World Health Organization (WHO) January 2019 report, around 50 million people are affected by epilepsy worldwide. Moreover, it is estimated that around 2.4 million new cases of epilepsy are diagnosed every year, globally. Increasing approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA) are highly contributing to increase in the anticonvulsants market revenue. There are around 24 anticonvulsants drugs approved by the FDA. In 2018, FDA approved the first drug containing an active ingredient derived from marijuana to treat rare, severe forms of epilepsy such as Lennox-Gastaut syndrome and Dravet syndrome.

6. Global Anticonvulsants Market: Regional Analysis North America is expected to hold dominant position in the anticonvulsants market during the forecast period, owing to increasing demand for treatment of epilepsy. For instance, according to the WHO 2019 report, in up to 70% of people living with epilepsy globally, seizure is controlled with appropriate diagnosis and use of anti-epileptic medicines. Low-cost treatment is available, with daily medication that costs US$ 5 per year. Asia Pacific anticonvulsants market revenue is expected to witness significant growth over the forecast period, owing to increasing prevalence of epilepsy in economies such as India, China, and Japan. According to the National Center for Biotechnology Information 2015 report, India has huge patient base of 12 million people affected by epilepsy.

7. Global Anticonvulsants Market: Competitive Landscape Key players operating in the global anticonvulsants market include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., UCB Group, Shire Plc., GlaxoSmithKline Plc., Cephalon Inc., and Astrazeneca Plc. Global Anticonvulsants Market: Taxonomy The global anticonvulsants market is segmented on the basis of drug class, application, route of administration, distribution channel, and region.

8. By Drug Class • Barbiturates • Benzodiazepines • Hydantoins • Succinimides • Others • By Application • Epilepsy • Migraine • Fibromyalgia • Neuropathic pain • Anxiety • Bipolar disorder • By Route of Administration • Enteral • Parenteral • Topical • By Distribution Channel • Retail Pharmacy • Hospital Pharmacy • Online Pharmacy • By Region • North America • Latin America • Europe • Asia Pacific • Middle East • Africa

9. Request Sample Report • Request Customization • Download PDF brochure • Talk To Analyst • Buy Now • Reference: https://www.coherentmarketinsights.com/ongoing-insight/anticonvulsants-market-2516

10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis

11. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/